Aligos director granted options on 5,860 shares

Aligos Therapeutics director Carole Nuechterlein received a new stock option grant.

Rhea-AI Filing Summary

Aligos Therapeutics director Carole Nuechterlein received a new stock option grant. She was awarded options to purchase 5,860 shares of Aligos Therapeutics common stock at an exercise price of $5.50 per share. Following this grant, she holds options for 5,860 underlying shares.

According to the award terms, the options will vest and become exercisable for 100% of the 5,860 shares on the earlier of the first anniversary of the grant date or immediately prior to the company’s 2027 annual stockholder meeting, subject to her continuous service through the vesting date. The options are scheduled to expire on June 25, 2036.

Insights

Equity compensation analyst

Routine option grant to director with standard time-based vesting.

This filing shows Aligos Therapeutics granting director Carole Nuechterlein stock options for 5,860 shares of common stock at an exercise price of $5.50 per share. The grant appears to be compensation-related rather than an open-market transaction.

The options vest in full on the earlier of the first anniversary of the grant or immediately before the 2027 annual stockholder meeting, contingent on continuous service. This is a typical one-year cliff vesting structure used for non-employee directors and does not change cash on the company’s balance sheet at grant.

The options expire on June 25, 2036, giving a long-dated incentive horizon tied to the company’s future share price performance. The filing does not indicate any 10b5-1 trading plan or related sales, so the event is best viewed as standard equity compensation rather than a market-sentiment signal.

Insider Trade Summary

Grant/Award: 5,860 shares

Grant/Award 1 txn

Insider Nuechterlein Carole

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,860	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 5,860 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

Key Figures

Option grant size: 5,860 shares Exercise price: $5.50 per share Post-grant option holdings: 5,860 shares +2 more

5 metrics

Option grant size 5,860 shares Underlying common stock in new director option award

Exercise price $5.50 per share Strike price for newly granted stock options

Post-grant option holdings 5,860 shares Total underlying shares subject to options after this grant

Option expiration date June 25, 2036 End of option term for this grant

Vesting schedule 100% cliff vesting Earlier of first anniversary or immediately prior to 2027 annual meeting

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"an exercise price of $5.50 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"options will vest and become exercisable for 100% of the 5,860 shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"The options are scheduled to expire on June 25, 2036"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aligos Therapeutics (ALGS) director Carole Nuechterlein report in this Form 4?

Director Carole Nuechterlein reported receiving a stock option grant for 5,860 shares of Aligos Therapeutics common stock. The options are an equity compensation award, not an open-market share purchase or sale, and give her the right to buy shares at a fixed exercise price.

How many Aligos Therapeutics (ALGS) shares are covered by the new stock options?

The new stock option grant covers 5,860 underlying shares of Aligos Therapeutics common stock. These options give the director the right, but not the obligation, to buy that number of shares in the future if the vesting and exercise conditions are satisfied.

What is the exercise price of Carole Nuechterlein’s Aligos Therapeutics (ALGS) stock options?

The exercise price of the stock options is set at $5.50 per share. This means the director can purchase Aligos Therapeutics common stock at $5.50 per share once the options vest, regardless of the market price at that future time.

When do the Aligos Therapeutics (ALGS) stock options granted to Carole Nuechterlein vest?

The options vest and become exercisable for 100% of the 5,860 shares on the earlier of the first anniversary of the grant date or immediately before the 2027 annual stockholder meeting, provided she maintains continuous service with Aligos Therapeutics through that vesting date.

When do Carole Nuechterlein’s Aligos Therapeutics (ALGS) stock options expire?

The stock options are scheduled to expire on June 25, 2036. After this expiration date, any unexercised options will lapse and no longer give the director the right to purchase Aligos Therapeutics common stock at the stated exercise price.

Does this Aligos Therapeutics (ALGS) Form 4 show a share purchase or sale in the market?

No, the Form 4 reflects a grant of stock options as compensation, not a market trade. The director did not buy or sell common shares on the open market; instead, she received options that may be exercised in the future if they vest and are in the money.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:36 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nuechterlein Carole

(Last) (First) (Middle)

C/O ALIGOS THERAPEUTICS, INC.

1 CORPORATE DRIVE, 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ ALGS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.5	06/25/2026		A		5,860		(1)	06/25/2036	Common Stock	5,860	$0	5,860	D

Explanation of Responses:

1. The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2027 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date.

	/s/ Lesley Ann Calhoun, as attorney-in fact for Carole Nuechterlein	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)